[Re-evaluation of immunomodulator treatments for recurrent abortions].

Rev Med Brux

Services d'Immunologie et de Transfusion, Hôpital Erasme, U.L.B.

Published: April 1998

Immunotherapy of spontaneous recurrent abortion is still a matter of controversy. Since 1985, 117 patients were treated in our center. Transfusions of paternal leucocytes (PL) were given to 56 patients and intravenous immunoglobulins (i.v.Ig) to 61 patients. The allocation of the two treatments was not randomised. Respectively 74% and 71% normal pregnancies were achieved. In two cases treated by paternal leucocytes, the appearance of anti-erythrocytes alloantibodies (anti c and anti Jkb + C) was noted. Two patients receiving i.v.Ig had a transient allergic reaction (urticaria). In the five patients presenting with spontaneous abortion in the setting of in vitro fecondation, four normal pregnancies were achieved. These encouraging results from a single center are still to be considered as preliminary but urge us on continuing this approach. One of the drawback of i.v.Ig is their cost. Use of paternal leucocytes constitutes an adequate alternative provided that a strict immunological selection of the father is performed to avoid lymphocyte or platelet alloimmunisation. Our results are discussed in the light of recent controlled studies emphasizing the importance of the placebo effect and in the light of the new concepts in pregnancy immunology (protective action of trophoblastic HLA-G and Th2 cytokines; antagonistic effect of endometrial NK cells.

Download full-text PDF

Source

Publication Analysis

Top Keywords

paternal leucocytes
12
normal pregnancies
8
pregnancies achieved
8
patients
5
[re-evaluation immunomodulator
4
immunomodulator treatments
4
treatments recurrent
4
recurrent abortions]
4
abortions] immunotherapy
4
immunotherapy spontaneous
4

Similar Publications

Objectives: Human leukocyte antigen G (HLA-G) plays a crucial role in pregnancy. Pregnancy loss (PL) is caused by a variety of causes, such as fetal chromosomal abnormalities, maternal hypertension and diabetes, immune causes, spontaneous immune diseases, infections, unknown causes, etc. This study reports on the association of fetal HLA-G 3'UTR polymorphisms and diplotypes with chromosomally abnormal fetuses (CAF) or unexplained pregnancy loss (UPL).

View Article and Find Full Text PDF

Background: It is not known whether bone marrow stem cells when injected intravenously for a bone marrow transplant colonize the human testicular epithelium. No previous studies of sperm genotype after bone marrow transplantation are reported.

Objectives: To differentiate host from donor genotype in spermatozoa of men who have undergone successful bone marrow transplants.

View Article and Find Full Text PDF

Oocyte donation (OD) pregnancies result in increased fetal-maternal immunogenetic dissimilarity due to paternal and donor-derived genes. Higher fetal-maternal HLA mismatches are correlated with preeclampsia. Therefore, this study explored the maternal immune response, focusing on regulatory T cells (Tregs) during low versus high allogeneic pregnancies, and healthy versus preeclamptic OD pregnancies.

View Article and Find Full Text PDF

Parental age at birth, telomere length, and autism spectrum disorders in the UK Biobank cohort.

Autism Res

November 2024

Department of Biobehavioral Health, The Pennsylvania State University, University Park, Pennsylvania, USA.

Older parental age at birth is associated with increased risk of autism spectrum disorders (ASD) in offspring. Independently, shorter telomere length (TL) has also been shown to be associated with ASD in children. However, older paternal age at birth, with or without controlling for maternal age, has been associated with longer TL, a seemingly contradictory finding.

View Article and Find Full Text PDF
Article Synopsis
  • * The research investigates the effects of adding paternal lymphocytes to maternal activated PBMCs during insemination, with patients divided into four groups based on the type and number of PBMCs used.
  • * Results indicate that using activated PBMCs increases clinical pregnancy rates across all groups, with the highest success observed in patients receiving both paternal and maternal activated PBMCs, achieving a clinical pregnancy rate of 47.2% and live birth rate of 41.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!